MX354127B - Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central. - Google Patents

Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.

Info

Publication number
MX354127B
MX354127B MX2014011612A MX2014011612A MX354127B MX 354127 B MX354127 B MX 354127B MX 2014011612 A MX2014011612 A MX 2014011612A MX 2014011612 A MX2014011612 A MX 2014011612A MX 354127 B MX354127 B MX 354127B
Authority
MX
Mexico
Prior art keywords
disorders
preventing
nervous system
central nervous
lysosomal storage
Prior art date
Application number
MX2014011612A
Other languages
English (en)
Other versions
MX2014011612A (es
Inventor
Boyd Robert
J Rybczynski Philip
Sheth Kamlesh
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2014011612A publication Critical patent/MX2014011612A/es
Publication of MX354127B publication Critical patent/MX354127B/es

Links

Classifications

    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/01—Manufacture or treatment
    • H10B12/02—Manufacture or treatment for one transistor one-capacitor [1T-1C] memory cells
    • H10B12/03—Making the capacitor or connections thereto
    • H10B12/033—Making the capacitor or connections thereto the capacitor extending over the transistor
    • H10B12/0335—Making a connection between the transistor and the capacitor, e.g. plug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer
    • H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic System or AIIIBV compounds with or without impurities, e.g. doping materials
    • H01L21/30—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26
    • H01L21/31—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26 to form insulating layers thereon, e.g. for masking or by using photolithographic techniques; After treatment of these layers; Selection of materials for these layers
    • H01L21/3105—After-treatment
    • H01L21/311—Etching the insulating layers by chemical or physical means
    • H01L21/31105—Etching inorganic layers
    • H01L21/31111—Etching inorganic layers by chemical means
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer
    • H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic System or AIIIBV compounds with or without impurities, e.g. doping materials
    • H01L21/30—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26
    • H01L21/31—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26 to form insulating layers thereon, e.g. for masking or by using photolithographic techniques; After treatment of these layers; Selection of materials for these layers
    • H01L21/3205—Deposition of non-insulating-, e.g. conductive- or resistive-, layers on insulating layers; After-treatment of these layers
    • H01L21/321—After treatment
    • H01L21/3213—Physical or chemical etching of the layers, e.g. to produce a patterned layer from a pre-deposited extensive layer
    • H01L21/32139—Physical or chemical etching of the layers, e.g. to produce a patterned layer from a pre-deposited extensive layer using masks
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L28/00—Passive two-terminal components without a potential-jump or surface barrier for integrated circuits; Details thereof; Multistep manufacturing processes therefor
    • H01L28/40—Capacitors
    • H01L28/60—Electrodes
    • H01L28/82—Electrodes with an enlarged surface, e.g. formed by texturisation
    • H01L28/90—Electrodes with an enlarged surface, e.g. formed by texturisation having vertical extensions
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/01—Manufacture or treatment
    • H10B12/02—Manufacture or treatment for one transistor one-capacitor [1T-1C] memory cells
    • H10B12/03—Making the capacitor or connections thereto
    • H10B12/033—Making the capacitor or connections thereto the capacitor extending over the transistor
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/01—Manufacture or treatment
    • H10B12/02—Manufacture or treatment for one transistor one-capacitor [1T-1C] memory cells
    • H10B12/05—Making the transistor
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/01—Manufacture or treatment
    • H10B12/09—Manufacture or treatment with simultaneous manufacture of the peripheral circuit region and memory cells
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10B—ELECTRONIC MEMORY DEVICES
    • H10B12/00—Dynamic random access memory [DRAM] devices
    • H10B12/30—DRAM devices comprising one-transistor - one-capacitor [1T-1C] memory cells
    • H10B12/31—DRAM devices comprising one-transistor - one-capacitor [1T-1C] memory cells having a storage electrode stacked over the transistor
    • H10B12/315—DRAM devices comprising one-transistor - one-capacitor [1T-1C] memory cells having a storage electrode stacked over the transistor with the capacitor higher than a bit line

Abstract

Se describen sales novedosas del compuesto (3R,4R,5S)-5-(difluorom etil)piperidin-3,4-diol, así como también métodos que las utilizan para prevenir y/o tratar tesaurismosis lisosámicas y/o trastornos degenerativos del sistema nervioso central. En particular, la presente invención proporciona métodos para prevenir y/o tratar la enfermedad de Gaucher y/o la enfermedad de Parkinson.
MX2014011612A 2012-03-27 2013-03-07 Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central. MX354127B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616159P 2012-03-27 2012-03-27
PCT/US2013/029612 WO2013148103A1 (en) 2012-03-27 2013-03-07 Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system

Publications (2)

Publication Number Publication Date
MX2014011612A MX2014011612A (es) 2014-10-17
MX354127B true MX354127B (es) 2018-02-14

Family

ID=47902369

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011612A MX354127B (es) 2012-03-27 2013-03-07 Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.

Country Status (9)

Country Link
US (3) US9464050B2 (es)
EP (1) EP2831043B1 (es)
AU (1) AU2013240486B2 (es)
CA (1) CA2868459A1 (es)
ES (1) ES2924829T3 (es)
HK (1) HK1205503A1 (es)
MX (1) MX354127B (es)
NZ (1) NZ630612A (es)
WO (1) WO2013148103A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028129T2 (en) * 2009-10-19 2016-11-28 Amicus Therapeutics Inc New preparations for the prevention and / or treatment of lysosomal storage disorders
JP2017502961A (ja) 2013-12-23 2017-01-26 アレクトス セラピューティックス インコーポレイテッド グルコセレブロシダーゼモジュレーターおよびその使用
AU2015217172B2 (en) * 2014-02-12 2019-09-19 Amicus Therapeutics, Inc. Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
CA3048357A1 (en) 2016-12-29 2018-07-05 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
CA2145418A1 (en) 1992-09-29 1994-04-14 John S. Patton Pulmonary delivery of active fragments of parathyroid hormone
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6794694B2 (en) 2000-12-21 2004-09-21 Agere Systems Inc. Inter-wiring-layer capacitors
JP4060572B2 (ja) 2001-11-06 2008-03-12 株式会社東芝 半導体記憶装置及びその製造方法
KR100446293B1 (ko) 2002-01-07 2004-09-01 삼성전자주식회사 저항체를 포함하는 반도체 소자 제조 방법
JP2003273230A (ja) 2002-03-19 2003-09-26 Nec Electronics Corp 半導体装置及びその製造方法
US6720232B1 (en) 2003-04-10 2004-04-13 Taiwan Semiconductor Manufacturing Company Method of fabricating an embedded DRAM for metal-insulator-metal (MIM) capacitor structure
BRPI0416216A (pt) * 2003-11-12 2006-12-26 Amicus Therapeutics Inc composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
US7425740B2 (en) 2005-10-07 2008-09-16 Taiwan Semiconductor Manufacturing Company, Ltd. Method and structure for a 1T-RAM bit cell and macro
JP2007201101A (ja) 2006-01-25 2007-08-09 Nec Electronics Corp 集積回路装置および回路製造方法
DE602007013648D1 (de) 2006-05-24 2011-05-19 Amicus Therapeutics Inc Tartratsalz aus Isofagomin und Verwendungsverfahren dafür
US9056101B2 (en) 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
CN105367485B (zh) 2009-10-19 2018-04-17 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性失调的新颖组合物
EP2957295B1 (en) * 2009-10-19 2017-08-02 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
HUE028129T2 (en) * 2009-10-19 2016-11-28 Amicus Therapeutics Inc New preparations for the prevention and / or treatment of lysosomal storage disorders
JP2012064627A (ja) 2010-09-14 2012-03-29 Elpida Memory Inc 半導体装置の製造方法
JP5689392B2 (ja) 2011-09-02 2015-03-25 ルネサスエレクトロニクス株式会社 半導体装置及び半導体装置の製造方法
KR102023720B1 (ko) 2012-09-03 2019-09-20 엘지이노텍 주식회사 보이스 코일 모터

Also Published As

Publication number Publication date
US20150050263A1 (en) 2015-02-19
AU2013240486A1 (en) 2014-09-25
US9464050B2 (en) 2016-10-11
MX2014011612A (es) 2014-10-17
US20170020853A1 (en) 2017-01-26
AU2013240486B2 (en) 2017-10-26
US20170365609A1 (en) 2017-12-21
EP2831043A1 (en) 2015-02-04
HK1205503A1 (en) 2015-12-18
EP2831043B1 (en) 2022-07-27
WO2013148103A1 (en) 2013-10-03
CA2868459A1 (en) 2013-10-03
NZ630612A (en) 2016-11-25
US10224333B2 (en) 2019-03-05
US9750733B2 (en) 2017-09-05
ES2924829T3 (es) 2022-10-11

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
MX354127B (es) Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
MX2010005648A (es) Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina.
WO2015011284A3 (en) Inhibitors of fapp2 and uses thereof
WO2008148801A8 (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
MX2013007702A (es) Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX365108B (es) Derivados piperidina para agonista gpr119.
TN2015000271A1 (en) New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
PH12013501321B1 (en) Phenoxymethyl heterocyclic compounds
TW200642690A (en) Composition for treating central nervous system disorders
WO2011147951A8 (en) Cycloamino derivatives as gpr119 agonists
SG10201804952QA (en) Glucosylceramide synthase inhibitors
NZ705813A (en) Treatment of mild and moderate alzheimer’s disease
TN2012000191A1 (en) Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands
GB201114389D0 (en) Novel compounds

Legal Events

Date Code Title Description
FG Grant or registration